|
|
| Product Name: | MLi-2 | | Synonyms: | MLi-2;rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole;1H-Indazole, 3-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[(1-methylcyclopropyl)oxy]-, rel-;rel-(2S,6R)-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine;MLi2,MLi-2,Inhibitor,Leucine-rich repeat kinase 2,inhibit,disease,orally,LRRK2,Parkinson’s,MLi 2 | | CAS: | 1627091-47-7 | | MF: | C21H25N5O2 | | MW: | 379.46 | | EINECS: | | | Product Categories: | | | Mol File: | 1627091-47-7.mol |  |
| | MLi-2 Chemical Properties |
| Boiling point | 625.8±55.0 °C(Predicted) | | density | 1.257±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 15 mg/ml | | form | A crystalline solid | | pka | 11.24±0.40(Predicted) |
| | MLi-2 Usage And Synthesis |
| Uses | MLi-2 is a leucine-rich repeat kinase 2 (LRRK2) inhibitor and may be used in the treatment and prevention of Parkinson’s disease as its a precursor to the illness. | | Definition | ChEBI: MLI-2 is a member of the class of indazoles that is 1H-indazole that is substituted at position 3 by a 6-(cis-2,6-dimethylmorpholin-4-yl)pyrimidin-4-yl group and at position 5 by a (1-methylcyclopropoxy)group. It is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is a member of indazoles, a member of pyrimidines, a member of morpholines, a member of cyclopropanes, an aromatic ether and a tertiary amino compound. | | storage | Store at -20°C |
| | MLi-2 Preparation Products And Raw materials |
|